The stock of ATAI Life Sciences N.V (ATAI) has gone up by 15.56% for the week, with a -14.29% drop in the past month and a 31.09% rise in the past quarter. The volatility ratio for the week is 7.95%, and the volatility levels for the past 30 days are 9.06% for ATAI. The simple moving average for the past 20 days is 3.50% for ATAI’s stock, with a 8.72% simple moving average for the past 200 days.
Is It Worth Investing in ATAI Life Sciences N.V (NASDAQ: ATAI) Right Now?
Company’s 36-month beta value is 1.19.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATAI is 131.31M, and currently, short sellers hold a 8.34% ratio of that floaft. The average trading volume of ATAI on March 25, 2025 was 2.88M shares.
ATAI) stock’s latest price update
The stock price of ATAI Life Sciences N.V (NASDAQ: ATAI) has plunged by -0.64 when compared to previous closing price of 1.57, but the company has seen a 15.56% gain in its stock price over the last five trading sessions. proactiveinvestors.com reported 2025-03-18 that atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company’s fourth quarter update. “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with H.C. Wainwright repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on November 18, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $6. The rating they have provided for ATAI stocks is “Buy” according to the report published on April 03rd, 2024.
Loop Capital gave a rating of “Buy” to ATAI, setting the target price at $18 in the report published on November 01st of the previous year.
ATAI Trading at -8.26% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.26% of loss for the given period.
Volatility was left at 9.06%, however, over the last 30 days, the volatility rate increased by 7.95%, as shares sank -7.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.33% upper at present.
During the last 5 trading sessions, ATAI rose by +18.15%, which changed the moving average for the period of 200-days by +13.12% in comparison to the 20-day moving average, which settled at $1.5090. In addition, ATAI Life Sciences N.V saw 17.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATAI starting from Kirpekar Sahil, who sale 48,563 shares at the price of $1.35 back on Mar 21 ’25. After this action, Kirpekar Sahil now owns 115,636 shares of ATAI Life Sciences N.V, valued at $65,560 using the latest closing price.
Craig Kevin James, the Chief Medical Officer of ATAI Life Sciences N.V, sale 11,563 shares at $1.35 during a trade that took place back on Mar 21 ’25, which means that Craig Kevin James is holding 8,437 shares at $15,610 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -333.06 for the present operating margin
- 0.46 for the gross margin
The net margin for ATAI Life Sciences N.V stands at -484.64. The total capital return value is set at -0.76. Equity return is now at value -62.43, with -50.86 for asset returns.
Based on ATAI Life Sciences N.V (ATAI), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -3.34. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -32.84.
Currently, EBITDA for the company is -144.81 million with net debt to EBITDA at -0.05. When we switch over and look at the enterprise to sales, we see a ratio of 1002.79. The receivables turnover for the company is 0.23for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In a nutshell, ATAI Life Sciences N.V (ATAI) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
